Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN) response has been demonstrated in patients with severe COVID-19, together with a high viral load. The aim of the current work is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as compared to patients having negative anti-IFN antibodies.
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress
syndrome (ARDS), which leads to a mortality of 30-40%. An altered type I interferon (IFN)
response has been demonstrated in patients with severe COVID-19, together with a high viral
load. A recent study revealed that 10% of patients admitted in the intensive care unit (ICU)
for severe COVID-19 had positive type I anti-IFN antibodies. Such finding has potentially
important therapeutic implications, as patients having positive anti-IFN antibodies could
benefit from targeted interventions, including plasmapheresis. The aim of the current work
is, in a large cohort of patients with severe COVID-19 admitted in the ICU, to determine the
prevalence of patients with positive anti-IFN antibodies and to determine their outcome, as
compared to patients having negative anti-IFN antibodies.
Inclusion Criteria:
- Age ≥ 18 years
- SARS-CoV-2 infection with a positive PCR
- Patient admitted in the ICU for acute respiratory failure (SpO2≤90% and need for
supplemental oxygen or any kind of ventilator support)
- Patient or next of keen was informed of study inclusion
Exclusion Criteria:
• Patient with SARS-CoV-infection but no acute respiratory failure
Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR
Créteil, France
Nicolas De PROST, MD, PhD, Study Chair
APHP